HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Endoscopic ultrasound-guided cyanoacrylate injection to prevent rebleeding in hepatocellular carcinoma patients with variceal hemorrhage.

AbstractBACKGROUND AND AIM:
Secondary prophylaxis (SP) of variceal rebleeding was reported to improve outcomes of hepatocellular carcinoma (HCC) patients, but the optimal endoscopic approach is not well defined. We compared outcomes in HCC patients who underwent SP by endoscopic ultrasound-guided cyanoacrylate obturation (EUS-CYA) versus no SP.
METHODS:
Between 2014 and 2018, 30 consecutive patients with inoperable HCC and recent endoscopically controlled variceal bleeding were prospectively recruited. Twenty-seven patients with persistent varices ≥ 3 mm on endoscopic ultrasound underwent EUS-CYA for SP. Thirty-three HCC patients treated by esophagogastroduodenoscopy-guided CYA obturation (EGD-CYA) alone for acute variceal bleeding between 2009 and 2013 were identified from a prospective gastrointestinal bleed registry as standard of care controls for comparison. Outcome measures were death-adjusted cumulative incidence of rebleeding, bleeding-free survival, technical success, and procedure-related adverse events of EUS-CYA.
RESULTS:
The majority of patients in both groups had advanced HCC, portal vein thrombosis, and Child-Pugh B cirrhosis. EUS-CYA was successful in all 27 patients with no radiographic evidence of cyanoacrylate-lipiodol embolization. Significantly lower 30- and 90-day death-adjusted cumulative incidence of rebleeding (14.8% vs 42.4%, P = 0.023 and 18.5% vs 60.6%, P = 0.002, respectively) and significantly higher variceal bleeding-free survival at 3 and 6 months (51.9% vs 21.2%, P = 0.009, 40.7% vs 15.2%, P = 0.010, respectively) were observed in the EUS-CYA group when compared with standard of care group.
CONCLUSIONS:
Secondary prophylaxis by EUS-CYA reduced rebleeding rate and improved variceal bleeding-free survival in patients with inoperable HCC and variceal bleeding when compared with no SP. Randomized studies are needed to confirm the benefits of EUS-CYA for this difficult-to-treat population.
AuthorsRaymond S Y Tang, Moe H Kyaw, Anthony Y B Teoh, Rashid N S Lui, Yee-Kit Tse, Thomas Y T Lam, Stephen L Chan, Vincent W S Wong, Justin C Y Wu, James Y W Lau, Joseph J Y Sung
JournalJournal of gastroenterology and hepatology (J Gastroenterol Hepatol) Vol. 35 Issue 12 Pg. 2192-2201 (Dec 2020) ISSN: 1440-1746 [Electronic] Australia
PMID32602261 (Publication Type: Journal Article)
Copyright© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Chemical References
  • Cyanoacrylates
Topics
  • Aged
  • Carcinoma, Hepatocellular (complications, mortality)
  • Cyanoacrylates (administration & dosage)
  • Endosonography (methods)
  • Esophageal and Gastric Varices (etiology)
  • Female
  • Gastrointestinal Hemorrhage (etiology, mortality, prevention & control)
  • Humans
  • Injections, Intralesional (methods)
  • Liver Neoplasms (complications)
  • Male
  • Middle Aged
  • Recurrence
  • Secondary Prevention
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: